Jeffrey L Cummings – Monoclonal antibodies in the treatment of Alzheimer’s disease
Jeffrey L Cummings (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV), a valued member of our editorial board for US Neurology, discusses how disease-modification is being approached for Alzheimer’s disease and the important emerging role of monoclonal antibodies, which are being used to target various biological targets in Alzheimer’s in clinical trials.
1. How is disease-modification being approached for Alzheimer’s disease (AD)? (0:12)
2. What role do monocloncal antibodies have in the treatment of AD? (0:43)
3. When in the course of AD should monocloncal antibodies be used? (1:32)
4. What are the biological targets of monocloncal antibodies? (2:47)
5. What are some of the promising monocloncal antibodies in trials now? (3:30)
6. What are the major challenges to developing monocloncal antibodies? (4:19)
Speaker disclosure: Jeffrey L Cummings has provided consultation to the following pharmaceutical companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies. Dr Cummings has provided consultation to Neurocog, MedAvante, and Bracket assessment companies, as well as the Global Alzheimer Platform (GAP) foundation. Dr Cummings owns stocks in Cummings owns stocks in ADAMAS, Alzheon, BioAsis, EIP Pharma, Prana, Sonexa, MedAvante, Neurotrax, and QR Pharma. Dr Cummings owns the copyright of the Neuropsychiatric Inventory, and receives research support from Avid and Teva. NIH support: COBRE grant# P20GM109025; TRC-PAD # R01AG053798; DIAGNOSE CTE # U01NS093334.
Filmed during a video call with Jeffrey L Cummings from his office at the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, US, May 2018.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study
The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what the study found in terms of the effect of discrimination on the cognitive function of this […]
Claire Sexton: Highlights of AAIC 2022
The Alzheimer’s Association International Conference (AAIC) is the largest and most influential meeting dedicated to advancing Alzheimer’s and dementia research. Each year, it gathers researchers to share discoveries that’ll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease. Dr Claire Sexton is the senior director of Scientific Programs […]
Dr Jennifer Bute: Living with dementia – the importance of laughter and hope
Dr Jennifer Bute is a retired GP living with dementia. She shares her experiences of diagnosis and describes the strategies that are helpful for her. Jennifer also highlights the importance of laughter, engagement and hope. Touch Medical Media is sharing educational resources on World Brain Day (22 July 2022) to help achieve brain health for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!